FDA head warns of backlash against pharma innovators in attack on “anti-competitive” patent strategies
US Food & Drug Administration (FDA) commissioner Scott Gottlieb has condemned the acquisition of large numbers of follow-on patent rights by branded drugs makers to extend their market monopolies. This patent thicketing, he argued, is one of several…
To read more
Register for limited access
Register to receive our weekly newsletter and access two of our subscriber-only articles per month.
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.